• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
March 4th - Bank of Japan Governor Kazuo Ueda stated on Wednesday that a significant increase in wage levels is needed for Japan to sustainably achieve its 2% inflation target. Speaking in parliament, Ueda said, "The Bank of Japan cannot exert a strong influence on real wage growth," which depends primarily on medium- to long-term labor productivity. He added, "However, we will implement monetary policy to ensure that Japan sustainably and stably achieves its inflation target while wages grow."March 4 – Lou Qinjian, spokesperson for the Fourth Session of the 14th National Peoples Congress, stated that safeguarding national sovereignty, security, and development interests is the starting point and ultimate goal of all foreign relations. The Taiwan question is Chinas internal affair and is the core of Chinas core interests. China firmly opposes the erroneous remarks made by Japanese leaders regarding Taiwan. The Chinese people will never allow any external forces to interfere in Chinas internal affairs and will resolutely safeguard national sovereignty, unity, and territorial integrity.Bank of Japan Governor Kazuo Ueda: If the economic and price trends are in line with our forecasts, we will continue to raise interest rates.Japans household consumer confidence index for February was 40, below the expected 38.2 and the previous reading of 37.9.March 4th - Since the outbreak of conflict in the Middle East this week, the yen has continued to weaken, deviating from its traditional safe-haven asset role, and Tokyo traders are preparing for possible government intervention. The yen has depreciated by about 1% since last Friday, to 157.2 yen to the dollar. Traders say this contrasts sharply with previous periods of geopolitical tension. Neil Newman, Japan strategist at Astris Advisory, said, "The yen is no longer a safe-haven asset. Companies stopped doing so about four years ago. They are now under pressure to the opposite, encouraged to invest overseas, and are still doing so on a large scale. In Japans current economic environment, there is no incentive to repatriate funds." Analysts say the yens unexpected weakness highlights structural changes and vulnerabilities in the Japanese economy. The market has been assessing the impact of Sanae Takashis expanded fiscal spending plan and her opposition to further interest rate hikes by the Bank of Japan. Tai Hui, chief market strategist for Asia Pacific at JPMorgan Asset Management, said increased exchange rate volatility has significantly reduced the yens appeal as a hedging currency. Geopolitical conflicts have also increased Japans exposure to rising energy prices and upside inflation risks.

Pfizer seeks U.S. approval for a reformulated Omicron vaccination booster

Aria Thomas

Aug 23, 2022 10:55

5.png


Pfizer Inc (NYSE:PFE) and its German partner BioNTech stated on Monday that they had submitted an application for U.S. approval of a COVID-19 vaccine booster modified to target the Omicron form and that doses would be available for distribution immediately following regulatory clearance.


The request to the Food and Drug Administration was for a bivalent vaccine containing both the widespread BA.4/BA.5 variants and the original coronavirus strain. It is intended for persons older than 12 years.


Pfizer indicated that it was set to fulfill a $3.2 billion contract with the United States government for 105 million doses, including Omicron-tailored injections, in September.


Albert Bourla, the chief executive officer of Pfizer, said in a statement, "We are prepared to immediately begin distribution of the bivalent Omicron BA.4/BA.5 boosters if approved."


Countries, including the United Kingdom, the United States, and members of the European Union, have prepared fall vaccination campaigns to protect against future outbreaks. The United Kingdom was the first nation to approve a bivalent immunization developed by Moderna last week (NASDAQ:MRNA).


Bourla announced on Twitter that Pfizer plans to finalize its submission to the European Medicines Agency in the next few days (NYSE:TWTR).


Similar to how annual changes to influenza vaccinations are handled, the FDA requested in June that COVID-19 vaccine producers modify injections to target the two sub variants and noted that it would not require new human testing studies for approval.


According to mid- to late-stage studies, Pfizer's older BA.1-tailored vaccine demonstrated a superior immune response against the subvariant.


This month, it is anticipated that a study of the BA.4/BA.5 vaccine in adults aged 12 and older would commence.